Angiogenesis modulators and therapeutics market research report

RITMIR007: Angiogenesis Modulators and Therapeutics – A Market Insight Report, July 2013
© RI Technologies - www.researchimpact.com Sample Page - 1
Angiogenesis Modulators and therapeutics Market size
Scope of the Study
This report gives an insight into the types of Angiogenesis Modulators – Inhibitors and Stimulators -and
their impact on various diseases. The study focuses on major angiogenesis inhibitors and their role in
diseases such as cancer, dermatology, ophthalmology, rheumatology and other angiogenesis based
diseases including endometriosis and inflammatory diseases. The emphasis is also given on major
angiogenesis stimulators and their role in diseases such as cardiovascular disorders including ischemia,
congestive heart failure, coronary artery disease, myocardial infarction and peripheral vascular disease and
chronic wound care. The study provides global market analysis for angiogenesis therapeutic products by
the above angiogenesis modulators and also by the disease areas such as cancer, cardiovascular disorders
and other angiogenesis based diseases. The study includes estimates and projections for the total global
angiogenesis therapeutic products market. Projections and estimates are also illustrated by geographic
regions encompassing United States, Europe, Asia-Pacific and Rest of World.
Business profiles of 34 major companies are discussed in the report. The report serves as a guide to global
angiogenesis industry, as it covers more than 325 companies that are engaged in angiogenesis research,
testing and supply of products and services. Major Contract Research Organizations and Universities
serving angiogenesis industry are also covered in the Corporate Directory section of this report.
Information related product developments, partnerships, collaborations, and mergers and acquisitions are
also covered in the report.
Angiogenesis Modulators report is an ideal research tool providing strategic business intelligence to the
corporate sector. This report may help strategists, investors, laboratories, pharmaceutical companies,
contract research organizations, biotechnology companies and drug approval authorities in--
 Gauging Competitive Intelligence
 Identifying Key Growth Areas and Opportunities
 Understanding Geographic Relevance to Product
 Knowing Regional Market Sizes and Growth Opportunities and Restraints
 Keeping Tab on Emerging Technologies
 Equity Analysis
 Tapping New Markets
Analytics and data presented in this report pertain to several parameters such as –
 Global And Regional Market Sizes, Market Shares, Market Trends
 Product (Global And Regional) Market Sizes, Market Shares, Market Trends
 Technology Trends
 Corporate Intelligence
 Key Companies By Sales, Brands, Products
 Consumer Behavioral Patterns

 Other Strategic Business Affecting Data
Research Methodology
RI Technologies publishes business intelligence reports by going through a cycle of diligent research and
analysis activity. Research is done using both online and offline resources. The study outline of this report is
sketched on the following lines – global market analysis, regional market analysis, product segmentation,
global and regional market analysis by product segment, market trends, M&A, R&D, competitive landscape,
technology trends, and other key drivers. Current data helps in analyzing the future of the industry and is
also helpful for doing market evaluations, and estimating the market size for the future.
This report is uniquely researched and the methodology includes:
 Need and Scope of Study
 Product Definitions
 Segmental Analysis
 Regional Analysis
 Exclusive Data Analytics
 Corporate Intelligence
 Feedback
Right from concept to final compilation of this report, both primary and secondary research methods are
applied. We have provided exclusive feedback forms/pre-release questionnaires for this report to use the
information for authentication of our own findings. Secondary research includes government publications,
investment research reports, web based surveys, website information of both companies and markets, and
other offline resources such as print publications and CDs.
Our compilation of easy to navigate PDF reports are essential value addition resources for leading and
growing companies.

II. REPORT SYNOPSIS
Angiogenesis
The process of growth of new blood vessels from the available vascular bed is termed as angiogenesis. In
general, this process takes place through development of embryo, during reproductive phase and wound
repair. In case of aberrations such as tumorous growth, atherosclerosis and diabetic retinopathy,
angiogenesis becomes inevitable due to variations in the positive and negative regulatory signals
restraining the process. A proper balance of tumor neovascularization would open new doors for
development of therapeutics for this disorder. The research patterns on anti-angiogenic drugs are focused
on establishing the clinical veracity of these drugs. The success in this field has been elevated with the
detection of improved role of hypoxia, growth factors, receptors, enzymes and bonding of cell molecules
involved in the process. These innovations in the field have facilitated development of various medical aids
such as receptor antagonists, and adhesion molecule blockers.
Angiogenesis is responsible for tumor development. These cells are generated by angiogenic molecules in
coordination with anti-angiogenic molecules. The growth of tumor is hindered or slowed down when the
anti-angiogenic components are initiated in the body to balance the angiogenic molecules.
This report analyzes global market for the following angiogenesis modulators and the therapeutic products
for angiogenesis based diseases. Synopsis chapter of the report gives the summary of the global market for
angiogenesis therapeutic products by angiogenesis modulators and by therapeutic areas for each
geographic region – the US, Europe, Asia-Pacific and Rest of World.
Segmentation
Exhibit 1. Segmentation of Global Angiogenesis Therapeutic Products Market by Angiogenesis
Modulators and Therapeutic Areas
Angiogenesis Modulators Therapeutic Areas
Angiogenesis Inhibitors Cancer
Angiogenesis Stimulators Cardiovascular
Ophthalmology
*Other
*Includes Alzheimer’s, dermatology, rheumatology, chronic wounds, endometriosis and inflammatory diseases
© RIT, 2013
Exhibit 2. Segmentation of Global Angiogenesis Cancer Therapeutic Products Market by Type
Cancer Type
Lung Cancer
Colorectal Cancer
Breast Cancer
*Other
*Includes Skin, Blood, Prostate, Renal Cell, Hepatocellular, Neuroendocrine, Esophageal,
Gastrointestinal stromal tumor (GIST), Ovarian, Pancreatic and Stomach Cancers
© RIT, 2013

Global Market Analysis
Global market for Angiogenesis therapeutic products is projected to reach about US$ XX.XX billion by 2020
from an estimated US$ XX.XX billion in 2012, growing at a compounded annual growth rate (CAGR) of
XX.XX% during the analysis period 2005-2020.
Exhibit 3. Angiogenesis Therapeutic Products – Global Value Market Estimations & Predictions (2005-
2020) in US$ Million
Year Value
2005 XX.XX
2006 XX.XX
2007 XX.XX
2008 XX.XX
2009 XX.XX
2010 XX.XX
2011 XX.XX
2012 XX.XX
2013 XX.XX
2014 XX.XX
2015 XX.XX
2016 XX.XX
2017 XX.XX
2018 XX.XX
2019 XX.XX
2020 XX.XX
CAGR% XX.XX
© RIT Figures, 2013
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
US$ Million

Angiogenesis Modulators Analysis by Geographic Region
Inhibitors
The market in Europe is projected to reach about US$ XX.XX billion for angiogenesis inhibitors by 2020 from
an estimated US$ XX.XX million in 2012, growing annually at a compounded rate of XX.XX % during the
period 2005-2020. In 2015, the market is estimated to touch US$ XX.XX million.
Germany was estimated the largest market in 2012 with market value of worth US$ XX.XX million, while United
Kingdom follows Germany with US$ XX.XXmillion. Switzerland, excluding Rest of Europe, is projected to be the
fastest growing market for angiogenesis inhibitors during 2005-2020 with a CAGR of XX.XX %.
Exhibit 4. Angiogenesis Inhibitors – European Value Market Estimations & Predictions (2005-2020) in US$
Million for Germany, United Kingdom, France, Switzerland and Rest of Europe
Year/Region Germany United Kingdom France Switzerland Rest of Europe Total
2005 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX
CAGR% XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
US$ Million
Germany United Kingdom France Switzerland Rest of Europe

III. MARKET DYNAMICS
MARKET OVERVIEW
Global Market Analysis
Global market for angiogenesis therapeutic products is projected to reach about US$ XX.XX billion by 2020
from an estimated US$ XX.XX billion in 2012, growing at a Compounded Annual Growth Rate (CAGR) of
XX.XX % during the analysis period, 2005-2020. Global Angiogenesis market for 2015 is estimated at US$
XX.XX billion.
The United States is the largest market for angiogenesis therapeutic products in 2012 with a share of XX.XX
%, valued at an estimated US$ XX.XX billion, and is projected to reach US$ XX.XX billion by 2020 to retain its
position with a share of XX.XX %. The US is also projected to be the second fastest growing market with a
CAGR of XX.XX %, excluding Rest of World, during the analysis period.
Europe is the second largest (XX.XX % market share in 2010) market during the same analysis period, while
Asia-Pacific is projected to be the fastest growing (XX.XX % during 2005-2020) market. In 2012, the market
for angiogenesis therapeutic products in Europe and Asia-Pacific is estimated at US$ XX.XX billion and US$
XX.XX billion respectively.
Rest of World (consisting of Latin America, Africa and Middle East) region’s market for angiogenesis
products is estimated at US$ XX.XX billion in 2012.

Exhibit 5. Angiogenesis Therapeutic Products – Global Value Market Estimations & Predictions (2005-
2020) in US$ Million for United States, Europe, Asia-Pacific and Rest of World
Year /Region United States Europe Asia-Pacific Rest of World Total
2005 XX.XX XX.XX XX.XX XX.XX XX.XX
CAGR% XX.XX XX.XX XX.XX XX.XX XX.XX
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
US$ Million
United States Europe Asia-Pacific Rest of World

IV. PRODUCT/TECHNOLOGY RESEARCH
Angiogenesis – The Growth of New Blood Vessels
The process of growth of new blood tissues from the available vascular bed is termed as Angiogenesis. In
general this process takes place through development of embryo, during reproductive phase and wound
repair. In case of aberrations like tumorous growth, atherosclerosis and diabetic retinopathy, angiogenesis
becomes inevitable due to variations in the positive and negative regulatory signals restraining the process.
A proper balance of tumor neovascularization would open new doors in development of therapeutics for
this disorder. The research patterns on anti-angiogenic drugs are focused to establish the clinical veracity of
these drugs. The success in this field has been elevated with the detection of improved role of hypoxia,
growth factors, receptors, enzymes and bonding of cell molecules involved in the process. These
innovations in the field have facilitated development of various medical aids such as receptor antagonists,
and adhesion molecule blockers.
Angiogenesis is the main system responsible for tumor development. These cells are generated by angiogenic
molecules in coordination with anti-angiogenic molecules. The growth of tumor is hindered or slowed down
when the anti-angiogenic components are initiated in the body to balance the angiogenic molecules.
The maximum limit of a tumor growth is 2 millimeters and is extendable along with vascularization. The role
played by angiogenesis in the development of tumor is very critical. It is responsible for supply of oxygen,
other nutrients to the cells and disposal of metabolic wastes effectively. Hence the tumor growth is
considered incomplete without the intervention of angiogenesis. Tumors obtain angiogenic phenotype during
a regular succession of the growth. This is considered as important biomarker for the treatment of cancer.
The tumor cells produce some significant angiogenic and anti-angiogenic molecules such as VEGF, bFGF,
angiostatin, and endostatin respectively. There is significant evidence to support this. Both these categories
of molecules have their own way of stimulating tumor angiogenesis. The balance between both these
molecules is the determinant of tumor growth. In most of the cases, as time elapses, mutational
inactivation in anti-angiogenic genes become responsible for balance of angiogenic molecules that
ultimately is responsible for tumor growth. Harmonizing of anti-angiogenic molecules over angiogenic
molecules would direct to the reticence of tumor growth and even deterioration.
The latest advancements in this field have enabled the development of numerous anti-angiogenic
components like angiostatin, endostatin and a few synthetic anti-angiogenic components. The large-scale
production of these components by employing recombinant DNA technique is being explored. Anti-
angiogenic molecules are responsible for regulation of apoptosis, minimizing of endothelial cell propagation
and some of the collective actions. The research with angiostatin and endostatin by employing model
animals has provided challenging results in the healing process of tumors and metastasis.
Anti-angiogenic factors play a vital role in the formation of new blood tissues from the normal cells. The
chemotherapeutic medicines attack the tumor cells. The repeated use of these therapies would reduce the
immunity of the body and breed various tissue related disorders. The research studies have highlighted the
negative effects of anti-angiogenic factors and their role in production of synergetic effects.

Exhibit 6. Angiogenesis Inhibitors (2005-2020): Global Analysis (Current & Future) of Patients Treated in
Million
Year Patients
2005 XX.XX
2006 XX.XX
2007 XX.XX
2008 XX.XX
2009 XX.XX
2010 XX.XX
2011 XX.XX
2012 XX.XX
2013 XX.XX
2014 XX.XX
2015 XX.XX
2016 XX.XX
2017 XX.XX
2018 XX.XX
2019 XX.XX
2020 XX.XX
CAGR% XX.XX
About RI Technologies
RI Technologies is a premier source of market research on the Biotechnology & Healthcare sector. We
emphasize on factual insights and forecasts with maximum global coverage. RI Technologies is constantly
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
Million

monitoring the biotechnology & Healthcare industry, tracking market trends, and forecasting industry
based on specialized analysis. The life sciences sector is an ever growing marketplace with emerging
technologies in areas of discovery, design and development.
Research – As Good as the Methodology is!
 Gauging Competitive Intelligence
 Identifying Key Growth Areas and Opportunities
 Understanding Geographic Relevance to Product
 Knowing Regional Market Sizes and Growth Opportunities and Restraints
 Keeping Tab on Emerging Technologies
 Equity Analysis
 Tapping New Markets
© COPYRIGHT
The copyright and publication rights to all RI Technologies' reports and other products are the property of
the company. Plagiarism of any kind accounts to violation of copyright laws. Any type of reproduction of
the material without express permission is not allowed. The buyer, under no circumstances, shall license,
resell or repackage, or sell data without prior permission of the company.
DISCLAIMER
RI Technologies sells content in good faith. The company is not liable to the buyer for any implications
arising out of the usage of data for any particular purpose. The company makes no representations or
warranties for the accuracy or completeness of the data. While extreme caution and effort is practiced for
data compilation and presentation, the company does not accept any responsibility for findings in the study
which are a cumulative effort of primary and secondary research resources. The studies do not endorse or
promote any product or company. RI Technologies, its affiliates, partners, distributors, and contractors are
not liable for inaccuracies or incompleteness of the reports. User discretion is recommended for the usage
of the data.

Angiogenesis modulators and therapeutics market research report

Recomendados

Recomendados

Más contenido relacionado

Más de Research Impact

Más de Research Impact (10)

Último

Último (20)

Angiogenesis modulators and therapeutics market research report